These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36356859)

  • 1. Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines.
    Tan AT; Lim JME; Bertoletti A
    Virol Sin; 2022 Dec; 37(6):783-785. PubMed ID: 36356859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
    Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
    Zhan H; Yang L; Liu Y; Li H; Li X; Wang H; Cao J; Kang S; Guo X; Dai E; Li Y
    J Infect; 2023 May; 86(5):e138-e141. PubMed ID: 36693568
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Wang H; Zhang Y; Huang B; Deng W; Quan Y; Wang W; Xu W; Zhao Y; Li N; Zhang J; Liang H; Bao L; Xu Y; Ding L; Zhou W; Gao H; Liu J; Niu P; Zhao L; Zhen W; Fu H; Yu S; Zhang Z; Xu G; Li C; Lou Z; Xu M; Qin C; Wu G; Gao GF; Tan W; Yang X
    Cell; 2020 Aug; 182(3):713-721.e9. PubMed ID: 32778225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
    Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
    Front Immunol; 2021; 12():742914. PubMed ID: 34659237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an inactivated vaccine candidate for SARS-CoV-2.
    Gao Q; Bao L; Mao H; Wang L; Xu K; Yang M; Li Y; Zhu L; Wang N; Lv Z; Gao H; Ge X; Kan B; Hu Y; Liu J; Cai F; Jiang D; Yin Y; Qin C; Li J; Gong X; Lou X; Shi W; Wu D; Zhang H; Zhu L; Deng W; Li Y; Lu J; Li C; Wang X; Yin W; Zhang Y; Qin C
    Science; 2020 Jul; 369(6499):77-81. PubMed ID: 32376603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Fadlyana E; Rusmil K; Tarigan R; Rahmadi AR; Prodjosoewojo S; Sofiatin Y; Khrisna CV; Sari RM; Setyaningsih L; Surachman F; Bachtiar NS; Sukandar H; Megantara I; Murad C; Pangesti KNA; Setiawaty V; Sudigdoadi S; Hu Y; Gao Q; Kartasasmita CB
    Vaccine; 2021 Oct; 39(44):6520-6528. PubMed ID: 34620531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
    Vadrevu KM; Reddy S; Jogdand H; Ganneru B; Mirza N; Tripathy VN; Singh C; Khalatkar V; Prasanth S; Rai S; Ella R; Blackwelder W; Prasad S; Ella K
    Lancet Infect Dis; 2022 Sep; 22(9):1303-1312. PubMed ID: 35717995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Audio Interview: How Well Are Covid-19 Vaccines Working?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
    [No Abstract]   [Full Text] [Related]  

  • 18. Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern.
    Xie T; Lu S; He Z; Liu H; Wang J; Tang C; Yang T; Yu W; Li H; Yang Y; Yang H; Yue L; Zhou Y; Yang F; Luo Z; Li Y; Xiang H; Zhao Y; Wang J; Wang H; Long R; Kuang D; Tan W; Peng X; Li Q; Xie Z
    Signal Transduct Target Ther; 2022 Feb; 7(1):61. PubMed ID: 35217639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Yorsaeng R; Suntronwong N; Phowatthanasathian H; Assawakosri S; Kanokudom S; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    Vaccine; 2022 Jan; 40(3):524-530. PubMed ID: 34893344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
    Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
    Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.